The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies
Harris WS, Del Gobbo L, Tintle NL
Atherosclerosis · 130 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2017-05-06 · Atherosclerosis · vol. 262 · págs. 51–54
- Editorial
- Elsevier BV
- Citado
- 183 citas · más que el 100% de estudios similares · 15.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 54 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Nutritional Studies and Diet · Aquaculture Nutrition and Growth
- Palabras clave
- omega-3 index, coronary heart disease mortality, eicosapentaenoic acid, docosahexaenoic acid, omega-3 fatty acids, hazard ratio, therapeutic target, biomarkers
- MeSH
- erythrocytes, humans, coronary disease, docosahexaenoic acids, eicosapentaenoic acid, prognosis, risk assessment, risk factors, cohort studies, time factors, protective factors, biomarkers, diet, healthy
3 autores
- William Stephen Harris🇺🇸 · autor de correspondenciaUniversity of South Dakota
- Liana C. Del Gobbo🇺🇸Stanford Medicine; Stanford University
- Nathan Tintle🇺🇸Dordt University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and aims
A recent 19-cohort meta-analysis examined the relationships between biomarkers of omega-3 fatty acids and risk for coronary heart disease (CHD). That study did not, however, report hazard ratios (HRs) specifically as a function of erythrocyte eicosapentaenoic (EPA) plus docosahexaenoic (DHA) levels, a metric called the Omega-3 Index in which EPA + DHA content is expressed as a percent of total fatty acids. The Omega-3 Index has been used in several recent studies and is a validated biomarker of omega-3 fatty acid tissue levels, but additional data are needed to confirm (or refute) the originally-proposed clinical cut-points of <4% (higher risk) and 8%-12% (lower risk).
Methods
The present study was therefore undertaken using published data from this meta-analysis to estimate HRs per 1-SD increase in the Omega-3 Index and median quintile values for this metric across 10 of the cohorts for which the needed data were available.
Results
The overall mean (SD) for the Omega-3 Index in these 10 cohort studies was 6.1% (2.1%), and the HR for a 1-SD increase was 0.85 (95% confidence interval, 0.80-0.91). Median quintile 1 and 5 levels were 4.2% vs. 8.3%, respectively. Based on these values, we estimate that risk for fatal CHD would have been reduced by about 30% moving from an Omega-3 Index of 4%-8%.
Conclusions
These findings support the use of 8% as reasonable therapeutic targets for the Omega-3 Index.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.